126 related articles for article (PubMed ID: 38886718)
21. Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy versus sulfonylurea monotherapy for people with type 2 diabetes and chronic kidney disease in Thailand.
Permsuwan U; Dilokthornsakul P; Thavorn K; Saokaew S; Chaiyakunapruk N
J Med Econ; 2017 Feb; 20(2):171-181. PubMed ID: 27645706
[TBL] [Abstract][Full Text] [Related]
22. The cost-effectiveness of a theory-based online health behaviour intervention for new university students: an economic evaluation.
Kruger J; Brennan A; Strong M; Thomas C; Norman P; Epton T
BMC Public Health; 2014 Sep; 14():1011. PubMed ID: 25262372
[TBL] [Abstract][Full Text] [Related]
23. Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: protection at what price in the Thai context?
Kulpeng W; Leelahavarong P; Rattanavipapong W; Sornsrivichai V; Baggett HC; Meeyai A; Punpanich W; Teerawattananon Y
Vaccine; 2013 Jun; 31(26):2839-47. PubMed ID: 23588084
[TBL] [Abstract][Full Text] [Related]
24. Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer.
Lam SW; Wai M; Lau JE; McNamara M; Earl M; Udeh B
Pharmacotherapy; 2017 Jan; 37(1):94-103. PubMed ID: 27870079
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn's disease using real world evidence in Thailand.
Phisalprapa P; Kositamongkol C; Limsrivilai J; Aniwan S; Charatcharoenwitthaya P; Pisespongsa P; Kitiyakara T; Treepongkaruna S; Chaiyakunapruk N
J Med Econ; 2020 Nov; 23(11):1302-1310. PubMed ID: 32729347
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness analysis of pharmacogenetic-guided warfarin dosing in Thailand.
Chong HY; Saokaew S; Dumrongprat K; Permsuwan U; Wu DB; Sritara P; Chaiyakunapruk N
Thromb Res; 2014 Dec; 134(6):1278-84. PubMed ID: 25456732
[TBL] [Abstract][Full Text] [Related]
27. Cost-Effectiveness Analysis of Sacubitril-Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction in Thailand.
Krittayaphong R; Permsuwan U
Am J Cardiovasc Drugs; 2018 Oct; 18(5):405-413. PubMed ID: 29926351
[TBL] [Abstract][Full Text] [Related]
28. Cost-Utility of Video-Electroencephalography Monitoring Followed by Surgery in Adults with Drug-Resistant Focal Epilepsy in Thailand.
Kitwitee P; Unnwongse K; Srikijvilaikul T; Yadee T; Limwattananon C
World Neurosurg; 2017 Feb; 98():750-760.e3. PubMed ID: 27913266
[TBL] [Abstract][Full Text] [Related]
29. Economic Evaluation of Intravenous Immunoglobulin plus Corticosteroids for the Treatment of Steroid-Resistant Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Thailand.
Bamrungsawad N; Upakdee N; Pratoomsoot C; Sruamsiri R; Dilokthornsakul P; Dechanont S; Wu DB; Dejthevaporn C; Chaiyakunapruk N
Clin Drug Investig; 2016 Jul; 36(7):557-66. PubMed ID: 27113227
[TBL] [Abstract][Full Text] [Related]
30. A Web-Based Computer-Tailored Alcohol Prevention Program for Adolescents: Cost-Effectiveness and Intersectoral Costs and Benefits.
Drost RM; Paulus AT; Jander AF; Mercken L; de Vries H; Ruwaard D; Evers SM
J Med Internet Res; 2016 Apr; 18(4):e93. PubMed ID: 27103154
[TBL] [Abstract][Full Text] [Related]
31. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
Armstrong EP
J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
[TBL] [Abstract][Full Text] [Related]
32. Evaluating the Cost Effectiveness of a Suicide Prevention Campaign Implemented in Ontario, Canada.
Lebenbaum M; Cheng J; de Oliveira C; Kurdyak P; Zaheer J; Hancock-Howard R; Coyte PC
Appl Health Econ Health Policy; 2020 Apr; 18(2):189-201. PubMed ID: 31535350
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness analysis of ultrasonography screening for nonalcoholic fatty liver disease in metabolic syndrome patients.
Phisalprapa P; Supakankunti S; Charatcharoenwitthaya P; Apisarnthanarak P; Charoensak A; Washirasaksiri C; Srivanichakorn W; Chaiyakunapruk N
Medicine (Baltimore); 2017 Apr; 96(17):e6585. PubMed ID: 28445256
[TBL] [Abstract][Full Text] [Related]
34. Iron-chelating therapies in a transfusion-dependent thalassaemia population in Thailand: a cost-effectiveness study.
Luangasanatip N; Chaiyakunapruk N; Upakdee N; Wong P
Clin Drug Investig; 2011; 31(7):493-505. PubMed ID: 21627338
[TBL] [Abstract][Full Text] [Related]
35. Cost effectiveness of rituximab and mycophenolate mofetil for neuromyelitis optica spectrum disorder in Thailand: Economic evaluation and budget impact analysis.
Aungsumart S; Apiwattanakul M
PLoS One; 2020; 15(2):e0229028. PubMed ID: 32050011
[TBL] [Abstract][Full Text] [Related]
36. An Economic Evaluation of Neonatal Screening for Inborn Errors of Metabolism Using Tandem Mass Spectrometry in Thailand.
Thiboonboon K; Leelahavarong P; Wattanasirichaigoon D; Vatanavicharn N; Wasant P; Shotelersuk V; Pangkanon S; Kuptanon C; Chaisomchit S; Teerawattananon Y
PLoS One; 2015; 10(8):e0134782. PubMed ID: 26258410
[TBL] [Abstract][Full Text] [Related]
37. The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol-dependent patients with high/very high drinking risk levels: a Markov model.
Laramée P; Brodtkorb TH; Rahhali N; Knight C; Barbosa C; François C; Toumi M; Daeppen JB; Rehm J
BMJ Open; 2014 Sep; 4(9):e005376. PubMed ID: 25227627
[TBL] [Abstract][Full Text] [Related]
38. Cost-Utility Analysis of Vericiguat in Heart Failure with Reduced Ejection Fraction After Worsening Heart Failure Events in China.
Chen P; Wang Y; Liu X; Yu J; Zheng X
Am J Cardiovasc Drugs; 2024 May; 24(3):445-454. PubMed ID: 38619802
[TBL] [Abstract][Full Text] [Related]
39. Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction.
Krittayaphong R; Permsuwan U
Int J Cardiol; 2021 Jan; 322():183-190. PubMed ID: 32800910
[TBL] [Abstract][Full Text] [Related]
40. Is Reconstruction of Unstable Midfoot Charcot Neuroarthropathy Cost Effective from a US Payer's Perspective?
Albright RH; Joseph RM; Wukich DK; Armstrong DG; Fleischer AE
Clin Orthop Relat Res; 2020 Dec; 478(12):2869-2888. PubMed ID: 32694315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
